Back to today’s briefing

Story perspectives

New Drug Combo Boosts Survival for Colorectal Cancer Patients

1/26/2025

33 5

Summary

Story summary

Colorectal cancer patients with Signatera-positive status saw remarkable improvements in their fight against the disease when celecoxib was added to standard chemotherapy. The CALGB/SWOG 80702 trial demonstrated a significant boost in disease-free survival (HR 0.55) and overall survival (HR 0.58), highlighting the critical role of ctDNA status in shaping effective treatment strategies.

1 of 1

Story summary

Colorectal cancer patients with Signatera-positive status saw remarkable improvements in their fight against the disease when celecoxib was added to standard chemotherapy. The CALGB/SWOG 80702 trial demonstrated a significant boost in disease-free survival (HR 0.55) and overall survival (HR 0.58), highlighting the critical role of ctDNA status in shaping effective treatment strategies.